Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
198 patients around the world
Available in Argentina
Bristol-Myers Squibb
198Patients around the world
This study is for people with
Heart failure
Requirements for the patient
To 90 Years
All Gender
Medical requirements
Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
Other protocol-defined Inclusion/Exclusion criteria apply.
